New Clinical Studies - Melanoma
- Study IMM-101-015 is designed to investigate the potential of IMM-101 alongside current first-line treatment in patients with advanced melanoma and is a natural progression from the encouraging survival seen in our previous studies in this disease
- Incidence of malignant melanoma is increasing every year and mortality rates of advanced melanoma patients remain high
- Treatment options increased with the approval of anti-PD1 immunotherapies (nivolumab and pembrolizumab) as first-line treatment for patients with advanced melanoma but over half of patients fail to respond to these immune checkpoint inhibitors and have very limited alternative treatment options
- Objectives of study IMM-101-015 are to investigate both the effectiveness of IMM 101 combined with nivolumab in controlling advanced melanoma and also the safety of the combination therapy
- These objectives will be assessed in two cohorts of patients, 18 previously untreated and 8 whose disease has progressed during anti-PD1 treatment
- Laboratory research provides support for the hypothesis that IMM-101 will improve the effectiveness of nivolumab and a recent publication by Dalgleish et al. (Journal of Translational Medicine 2018 16:227-233) describes 4 advanced melanoma patients treated with IMM-101 combined with immune checkpoint inhibitors who showed significant responses with no additional toxicity
- Study IMM-101-015 began recruiting patients in September 2018
Pancreatic Cancer
We are collaborating with MyTomorrows to facilitate early access to IMM-101 for cancer patients. EAPs (also known as “Expanded Access Program” or “Named-Patient Use”) offer an ethical, compliant, and controlled way of providing treatment with a medicine currently not licensed in a patient’s country of residence. Eligible patients for an EAP are in high medical need, cannot participate in a Clinical Trial, and have exhausted all registered treatment options. Initially treatment will be available for patients with advanced pancreatic cancer.